Choksi Laboratories Limited has submitted a regulatory disclosure to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure concerns an inspection conducted by the United States Food & Drug Administration (USFDA) at the company's central laboratory located at Indore. The inspection period was from August 17, 2026 to August 20, 2026.
Upon conclusion of the inspection, the company received 4 (Four) observations from the USFDA. The company states that it is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe.
The company reaffirms its commitment to fully comply with USFDA regulations and maintain the highest standards of quality and regulatory compliance at all times.